g12d
Entity, reached from Hormuz.
- Evidence
- 75 documents · 42 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 12 Apr 2026, last seen 9 Oct 2026
- Measured
- 21% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- Endpoints News · 2026-09-29 · Merck licenses a KRAS G12D inhibitor for $400M upfront (opens the source in a new tab)
- Fierce Biotech · 2026-09-28 · Merck pens $2.1B deal with China’s SciBrunch to chase KRAS G12D (opens the source in a new tab)
- Cancer Cell · 2026-09-16 · Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. (opens the source in a new tab)
- Nat Med · 2026-09-15 · Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial. (opens the source in a new tab)
- bioRxiv · 2026-09-15 · Hras G12V induces follicular thyroid cancer with attenuated MAPK activation and increased latency compared to Kras G12D. (opens the source in a new tab)
- J Med Chem · 2026-09-10 · Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations. (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with kras (74 documents)seen together
- co-mentioned with pancreatic cancer (18 documents)seen together
- co-mentioned with colorectal cancer (17 documents)seen together
- co-mentioned with lung cancer (15 documents)seen together
- co-mentioned with pdac (10 documents)seen together
- co-mentioned with solid tumors (9 documents)seen together